Huijin Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Huijin Feng has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Anupriya Singhal
Department of Medicine, Memorial Sloan Kettering Cancer Center , New York, 10065, NY
10 shared publications - Doron Betel
Applied Bioinformatics Core, Weill Cornell Medicine, New York, USA
10 shared publications - Elisa de Stanchina
Antitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA
10 shared publications - Hannah C. Styers
Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
10 shared publications - Hulya Sahin Ozkan
David M. Rubenstein Center for Pancreas Cancer Research, Memorial Sloan Kettering Cancer Center, New York, USA
10 shared publications - Iok In Christine Chio
Department of Genetics and Development, Institute for Cancer Genetics, Columbia University Irving Medical Center, New York, New York
10 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-6 from A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer
Supplementary Figure 1. KRAS inhibition promotes a classical differentiation state in mouse models of PDAC. Supplementary Figure 2. Gene expression analyses of KPF PDAC cells upon KRAS inhibition. Supplementary Figure 3. Generation and validation of a genetic reporter model to study classical cancer state dynamics in vivo. Supplementary Figure 4. In vivo dynamics of the classical state utilizing a distinct genetic reporter model. Supplementary Figure 5. Classical PDAC cells drive resistance to KRAS inhibition upon spontaneous tumor relapse. Supplementary Figure 6. KRAS inhibition promotes a classical cancer cell state in human PDAC.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-6 from A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer
Supplementary Figure 1. KRAS inhibition promotes a classical differentiation state in mouse models of PDAC. Supplementary Figure 2. Gene expression analyses of KPF PDAC cells upon KRAS inhibition. Supplementary Figure 3. Generation and validation of a genetic reporter model to study classical cancer state dynamics in vivo. Supplementary Figure 4. In vivo dynamics of the classical state utilizing a distinct genetic reporter model. Supplementary Figure 5. Classical PDAC cells drive resistance to KRAS inhibition upon spontaneous tumor relapse. Supplementary Figure 6. KRAS inhibition promotes a classical cancer cell state in human PDAC.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer
Supplementary Table 1 includes gene set enrichment analysis (GSEA) of KPF mouse PDAC cells comparing MRTX1133-treated vs. vehicle-treated classical and basal cells
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer
Supplementary Table 1 includes gene set enrichment analysis (GSEA) of KPF mouse PDAC cells comparing MRTX1133-treated vs. vehicle-treated classical and basal cells
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer
Supplementary Methods includes additional detailed experimental methodology and description of computational analyses.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer
Supplementary Methods includes additional detailed experimental methodology and description of computational analyses.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer
Supplementary Table 2 includes primer sequences and antibodies used in this study.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer
Supplementary Table 2 includes primer sequences and antibodies used in this study.
- Open Access
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer
Supplementary Methods includes additional detailed experimental methodology and description of computational analyses.
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer
Supplementary Methods includes additional detailed experimental methodology and description of computational analyses.
- Open Access
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-6 from A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer
Supplementary Figure 1. KRAS inhibition promotes a classical differentiation state in mouse models of PDAC. Supplementary Figure 2. Gene expression analyses of KPF PDAC cells upon KRAS inhibition. Supplementary Figure 3. Generation and validation of a genetic reporter model to study classical cancer state dynamics in vivo. Supplementary Figure 4. In vivo dynamics of the classical state utilizing a distinct genetic reporter model. Supplementary Figure 5. Classical PDAC cells drive resistance to KRAS inhibition upon spontaneous tumor relapse. Supplementary Figure 6. KRAS inhibition promotes a classical cancer cell state in human PDAC.
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-6 from A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer
Supplementary Figure 1. KRAS inhibition promotes a classical differentiation state in mouse models of PDAC. Supplementary Figure 2. Gene expression analyses of KPF PDAC cells upon KRAS inhibition. Supplementary Figure 3. Generation and validation of a genetic reporter model to study classical cancer state dynamics in vivo. Supplementary Figure 4. In vivo dynamics of the classical state utilizing a distinct genetic reporter model. Supplementary Figure 5. Classical PDAC cells drive resistance to KRAS inhibition upon spontaneous tumor relapse. Supplementary Figure 6. KRAS inhibition promotes a classical cancer cell state in human PDAC.
- Open Access
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer
Supplementary Table 1 includes gene set enrichment analysis (GSEA) of KPF mouse PDAC cells comparing MRTX1133-treated vs. vehicle-treated classical and basal cells
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer
Supplementary Table 1 includes gene set enrichment analysis (GSEA) of KPF mouse PDAC cells comparing MRTX1133-treated vs. vehicle-treated classical and basal cells
- Open Access
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer
Supplementary Table 2 includes primer sequences and antibodies used in this study.
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer
Supplementary Table 2 includes primer sequences and antibodies used in this study.
- Open Access
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Data from A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer
Intratumoral heterogeneity in pancreatic ductal adenocarcinoma (PDAC) is characterized by a balance between basal and classical epithelial cancer cell states, with basal dominance associating with chemoresistance and a dismal prognosis. Targeting oncogenic KRAS, the primary driver of pancreatic cancer, shows early promise in clinical trials, but efficacy is limited by acquired resistance. Using genetically engineered mouse models and patient-derived xenografts, we find that basal PDAC cells are highly sensitive to KRAS inhibitors. Employing fluorescent and bioluminescent reporter systems, we longitudinally track cell-state dynamics in vivo and reveal a rapid, KRAS inhibitor–induced enrichment of the classical state. Lineage tracing uncovers that these enriched classical PDAC cells are a reservoir for disease relapse. Genetic or chemotherapy-mediated ablation of the classical cell state is synergistic with KRAS inhibition, providing a preclinical proof of concept for this therapeutic strategy. Our findings motivate combining classical state–directed therapies with KRAS inhibitors to deepen responses and counteract resistance in pancreatic cancer.Significance: KRAS inhibitors hold promise in pancreatic cancer, but responses are limited by acquired resistance. We find that a classical epithelial cancer cell state is acutely resistant to KRAS inhibition and serves as a reservoir for disease relapse. Targeting the classical state alongside KRAS inhibition deepens responses, revealing a potent therapeutic strategy.See related commentary by Marasco and Misale, p. 2018
- 1 November 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer
Intratumoral heterogeneity in pancreatic ductal adenocarcinoma (PDAC) is characterized by a balance between basal and classical epithelial cancer cell states, with basal dominance associating with chemoresistance and a dismal prognosis. Targeting oncogenic KRAS, the primary driver of pancreatic cancer, shows early promise in clinical trials, but efficacy is limited by acquired resistance. Using genetically engineered mouse models and patient-derived xenografts, we find that basal PDAC cells are highly sensitive to KRAS inhibitors. Employing fluorescent and bioluminescent reporter systems, we longitudinally track cell-state dynamics in vivo and reveal a rapid, KRAS inhibitor–induced enrichment of the classical state. Lineage tracing uncovers that these enriched classical PDAC cells are a reservoir for disease relapse. Genetic or chemotherapy-mediated ablation of the classical cell state is synergistic with KRAS inhibition, providing a preclinical proof of concept for this therapeutic strategy. Our findings motivate combining classical state–directed therapies with KRAS inhibitors to deepen responses and counteract resistance in pancreatic cancer.Significance: KRAS inhibitors hold promise in pancreatic cancer, but responses are limited by acquired resistance. We find that a classical epithelial cancer cell state is acutely resistant to KRAS inhibition and serves as a reservoir for disease relapse. Targeting the classical state alongside KRAS inhibition deepens responses, revealing a potent therapeutic strategy.See related commentary by Marasco and Misale, p. 2018
- Top Cited Papers
- 5 July 2024
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 14 (11) , 2122-2134
A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer
Intratumoral heterogeneity in pancreatic ductal adenocarcinoma (PDAC) is characterized by a balance between basal and classical epithelial cancer cell states, with basal dominance associating with chemoresistance and a dismal prognosis. Targeting oncogenic KRAS, the primary driver of pancreatic cancer, shows early promise in clinical trials, but efficacy is limited by acquired resistance. Using genetically engineered mouse models and patient-derived xenografts, we find that basal PDAC cells are highly sensitive to KRAS inhibitors. Employing fluorescent and bioluminescent reporter systems, we longitudinally track cell-state dynamics in vivo and reveal a rapid, KRAS inhibitor–induced enrichment of the classical state. Lineage tracing uncovers that these enriched classical PDAC cells are a reservoir for disease relapse. Genetic or chemotherapy-mediated ablation of the classical cell state is synergistic with KRAS inhibition, providing a preclinical proof of concept for this therapeutic strategy. Our findings motivate combining classical state–directed therapies with KRAS inhibitors to deepen responses and counteract resistance in pancreatic cancer. Significance: KRAS inhibitors hold promise in pancreatic cancer, but responses are limited by acquired resistance. We find that a classical epithelial cancer cell state is acutely resistant to KRAS inhibition and serves as a reservoir for disease relapse. Targeting the classical state alongside KRAS inhibition deepens responses, revealing a potent therapeutic strategy. See related commentary by Marasco and Misale, p. 2018
- 5 July 2024
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 14 (11) , 2122-2134
Top Cited PapersA Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer
Intratumoral heterogeneity in pancreatic ductal adenocarcinoma (PDAC) is characterized by a balance between basal and classical epithelial cancer cell states, with basal dominance associating with chemoresistance and a dismal prognosis. Targeting oncogenic KRAS, the primary driver of pancreatic cancer, shows early promise in clinical trials, but efficacy is limited by acquired resistance. Using genetically engineered mouse models and patient-derived xenografts, we find that basal PDAC cells are highly sensitive to KRAS inhibitors. Employing fluorescent and bioluminescent reporter systems, we longitudinally track cell-state dynamics in vivo and reveal a rapid, KRAS inhibitor–induced enrichment of the classical state. Lineage tracing uncovers that these enriched classical PDAC cells are a reservoir for disease relapse. Genetic or chemotherapy-mediated ablation of the classical cell state is synergistic with KRAS inhibition, providing a preclinical proof of concept for this therapeutic strategy. Our findings motivate combining classical state–directed therapies with KRAS inhibitors to deepen responses and counteract resistance in pancreatic cancer. Significance: KRAS inhibitors hold promise in pancreatic cancer, but responses are limited by acquired resistance. We find that a classical epithelial cancer cell state is acutely resistant to KRAS inhibition and serves as a reservoir for disease relapse. Targeting the classical state alongside KRAS inhibition deepens responses, revealing a potent therapeutic strategy. See related commentary by Marasco and Misale, p. 2018